Ethinyloestradiol 20 mcg with desogestrel 150 mcg and 7 inert tablets (Mercilon 28)
We fully funded Mercilon 28 from 14 December 2020 until 31 March 2021 to ensure people could access oral contraceptives while we had supply issues with a number of brands.
Full funding for Mercilon 28
We are currently consulting on a proposal to fully fund Mercilon 28 for everyone. Submissions close on 12 March 2021.
23 November 2020 update
Previously, Mercilon 28 was only partially funded for most patients. It was only fully funded as a second line treatment for low income patients.
PHARMAC’s expert clinical advisors have told us that Mercilon 28 may be a suitable alternative for patients:
- who cannot tolerate combined oral contraceptives containing ethinyloestradiol with levonorgestrel (Microgynon 20 ED and Levlen ED), or
- where a progesterone only pill or long acting reversible contraceptive is unsuitable.